First 10 drugs chosen for Medicare price negotiations

August 29, 2023 2 min read Source/Disclosures Disclosures: Becerra and Brooks-LaSure report no financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . " data-action"subscribe"> Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: The first 10 drugs subject to Medicare price negotiations include diabetes, heart failure and rheumatoid arthritis treatments, among others. Negotiated prices would not take effect until 2026. HHS announced the first 10 drugs that will be subject to Medicare price negotiations. The Inflation Reduction Act, a law meant to lower health care costs for millions of Americans, included a provision that allows Medicare to negotiate the costs of prescription drugs. In 2022, Medicare enrollees who were taking the drugs chosen for negotiations paid a total of $3.4 billion in out-of-pocket costs, according to a press release from HHS. The HHS announced the first 10 drugs selected for price negotiations in Medicare on Tuesday. Negotiations will take place in 2023 and 2024, and new prices would become effective in 2026, but CMS plans to publish any new negotiated prices by Sept. 1, 2024. “Today marks a significant and historic moment for the Medicare program with the announcement of the first drugs selected for Medicare drug price negotiation,” CMS Administrator Chiquita Brooks-LaSure said in another press release. “Our goal with these negotiations is to improve access to some of the costliest drugs for millions of people with Medicare while driving competition and innovation.” According to a White House fact sheet, the first 10 drugs selected for Medicare price negotiation include: Eliquis (apixaban, Bristol Myers Squibb and Pfizer), which prevents and treats blood clots; Enbrel (etanercept, Amgen), which treats psoriasis, psoriatic arthritis and rheumatoid arthritis; Entresto (sacubitril/valsartan, Novartis), which treats heart failure; Farxiga (dapagliflozin, AstraZeneca), which treats chronic kidney disease, diabetes and heart failure; Imbruvica (ibrutinib, Janssen), which treats blood cancers; Januvia (sitagliptin, Merck), which treats diabetes; Jardiance (empagliflozin, Boehringer Ingelheim), which treats diabetes and heart failure; Stelara (ustekinumab, Janssen), which treats Crohn’s disease, psoriasis, psoriatic arthritis and ulcerative colitis; Xarelto (rivaroxaban, Janssen), which prevents and treats blood clots and reduces risk for patients with coronary or peripheral artery disease; and Several types of insulin treatments, including Fiasp, Fiasp FlexTouch and Fiasp PenFill (all manufactured by novoMEDLINK), as well as NovoLog, NovoLog FlexPen and NovoLog PenFill (all manufactured by Novo Nordisk). Medicare will negotiate prices for up to 60 drugs covered under Medicare parts B and D over the next 4 years, and up to an additional 20 drugs each year following that, according to the fact sheet. “For far too long, pharmaceutical companies have made record profits while American families were saddled with record prices and unable to afford lifesaving prescription drugs,” HHS Secretary Xavier Becerra said in the HHS release. “But thanks to the landmark Inflation Reduction Act, we are closer to reaching President Biden’s goal of increasing availability and lowering prescription drug costs for all Americans. Although drug companies are attempting to block Medicare from being able to negotiate for better drug prices, we will not be deterred.” References: ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . " data-action"subscribe"> Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Healio Special Report: Health Care and Politics Sources 1/ https://Google.com/ 2/ https://www.healio.com/news/primary-care/20230829/first-10-drugs-chosen-for-medicare-price-negotiations The mention sources can contact us to remove/changing this article

ExBulletin

First 10 drugs chosen for Medicare price negotiations

Health

First 10 drugs chosen for Medicare price negotiations

Key takeaways:

References:

Healio Special Report: Health Care and Politics

Related

Recent Posts

Add ExBulletin to your Home screen!